Hormonal
Earlier age at menarche (specifically onset before 11 years) is associated with a significantly higher risk of developing type 2 diabetes and elevated cardiometabolic risk factors in adult women, independent of early-adulthood BMI.
For women who experienced early puberty (before age 11), there is a statistically higher baseline risk for type 2 diabetes and metabolic issues later in life, independent of their current weight. This does not mean diabetes is inevitable, but it suggests that metabolic monitoring (e.g., checking HbA1c, fasting glucose, and lipids) should be prioritized earlier and more frequently than for those with later menarche, starting in early adulthood.
Menarche onset < 11 years [vs. 13-14 years (referent)] was associated with higher risk of diabetes (RR = 1.34; 95% CI: 1.14-1.57) after adjusting for sociodemographic factors, maternal education, maternal and paternal diabetes, and birth weight. This persisted after further control for BMI at age 20 years and relative leg length.
Why this rating
Large prospective cohort (n=8,075), rigorous adjustment for confounders, but relies on retrospective self-report for the primary exposure.
Source
Earlier age at menarche is associated with higher diabetes risk and cardiometabolic disease risk factors in Brazilian adults: Brazilian Longitudinal Study of Adult Health (ELSA-Brasil)
Noel T. Mueller et al. · Cardiovascular Diabetology · 2014
DOI 10.1186/1475-2840-13-22
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →